ZVSA on OTC
ZyVersa Therapeutics, Inc.
American pharmaceutical preparations company, incorporated in Delaware. Summary from the record
Price unavailable
Last updated Oct 19, 2026.
Overview
- TickerZVSA on OTC1
- IndustryPharmaceutical Preparations1
- HeadquartersLighthouse Point, Florida1
- Incorporated inDE2
- Business address2436 North Federal Highway, Suite 466, Lighthouse Point, Fl 330642
- Filer categoryNon-accelerated filer, Smaller reporting company, Emerging growth company2
See how the biggest companies compare on our leaderboards
100’s preclinical data, refer to the IC 100 White Paper at https://investors.zyversa.com/static-files/64964310-ab95-4a06-bc47-dd44c63dc5c7.3 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.6
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Research and development | $1.1M | $1.8M |
| General and administrative | $5.7M | $7.4M |
| Impairment of in-process research and development | $18.6M | |
| Total Operating Expenses | $25.5M | $9.1M |
| Loss From Operations | -$25.5M | -$9.1M |
| Interest expense | $513.2K | $269.9K |
| Change in fair value of equity payable | -$201.9K | |
| Pre-Tax Net Loss | -$25.8M | -$9.4M |
| Income tax benefit (provision) | $851.7K | -$6.7K |
| Net Loss | -$25.0M | -$9.4M |
| Basic | -$4.18 | -$8.48 |
| Diluted | -$4.18 | -$8.48 |
| Basic | 6.0M shares | 1.1M shares |
| Diluted | 6.0M shares | 1.1M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.6
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash | $101.8K | $1.5M | |
| Prepaid expenses and other current assets | $231.6K | $184.9K | |
| Vendor deposits | $14.5K | ||
| Total Current Assets | $347.9K | $1.7M | |
| In-process research and development | $18.6M | ||
| Vendor deposit | $178.5K | ||
| Deferred offering costs | $57.2K | ||
| Total Assets | $347.9K | $20.6M | |
| Accounts payable | $10.1M | $9.3M | |
| Accrued expenses and other current liabilities | $2.6M | $1.9M | |
| Total Current Liabilities | $12.7M | $11.2M | |
| Deferred tax liability | $851.7K | ||
| Total Liabilities | $12.7M | $12.1M | |
| Common stock | $809 | $251 | |
| Additional paid-in-capital | $125.2M | $121.2M | |
| Accumulated deficit | -$137.6M | -$112.6M | |
| Treasury stock, at cost, 7 shares at December 31, 2025 and 2024 | -$7.2K | -$7.2K | |
| Total Stockholders (Deficit) Equity | -$12.4M | $8.5M | $11.1M |
| Total Liabilities and Stockholders (Deficit) Equity | $347.9K | $20.6M | |
| Preferred stock, par value | $0.00 | $0.00 | |
| Preferred stock, shares authorized | 1.0M shares | 1.0M shares | |
| Common stock, par value | $0.00 | $0.00 | |
| Common stock, shares authorized | 250.0M shares | 250.0M shares | |
| Common stock, shares issued | 8.1M shares | 2.5M shares | |
| Common stock, shares outstanding | 8.1M shares | 2.5M shares | |
| Treasury stock, shares | 7 shares | 7 shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash | $101.8K | $1.5M | |
| Prepaid expenses and other current assets | $231.6K | $184.9K | |
| Vendor deposits | $14.5K | ||
| Total Current Assets | $347.9K | $1.7M | |
| In-process research and development | $18.6M | ||
| Vendor deposit | $178.5K | ||
| Deferred offering costs | $57.2K | ||
| Total Assets | $347.9K | $20.6M | |
| Accounts payable | $10.1M | $9.3M | |
| Accrued expenses and other current liabilities | $2.6M | $1.9M | |
| Total Current Liabilities | $12.7M | $11.2M | |
| Deferred tax liability | $851.7K | ||
| Total Liabilities | $12.7M | $12.1M | |
| Common stock | $809 | $251 | |
| Additional paid-in-capital | $125.2M | $121.2M | |
| Accumulated deficit | -$137.6M | -$112.6M | |
| Treasury stock, at cost, 7 shares at December 31, 2025 and 2024 | -$7.2K | -$7.2K | |
| Total Stockholders (Deficit) Equity | -$12.4M | $8.5M | $11.1M |
| Total Liabilities and Stockholders (Deficit) Equity | $347.9K | $20.6M | |
| Preferred stock, par value | $0.00 | $0.00 | |
| Preferred stock, shares authorized | 1.0M shares | 1.0M shares | |
| Common stock, par value | $0.00 | $0.00 | |
| Common stock, shares authorized | 250.0M shares | 250.0M shares | |
| Common stock, shares issued | 8.1M shares | 2.5M shares | |
| Common stock, shares outstanding | 8.1M shares | 2.5M shares | |
| Treasury stock, shares | 7 shares | 7 shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.6
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$25.0M | -$9.4M |
| Impairment of in-process research and development | $18.6M | |
| Stock-based compensation | $222.8K | $705.6K |
| Issuance of common stock pursuant to vendor agreements | $240.0K | $196.8K |
| Write-off of deferred offering costs | $57.2K | |
| Depreciation of fixed assets | $6.9K | |
| Non-cash rent expense | $7.8K | |
| Deferred tax (benefit) provision | -$851.7K | $6.7K |
| Prepaid expenses and other current assets | -$46.8K | $30.6K |
| Accounts payable | $689.3K | $888.6K |
| Vendor deposits | $161.9K | -$80.0K |
| Operating lease liability | -$8.7K | |
| Accrued expenses and other current liabilities | $717.3K | $139.5K |
| Net Cash Used In Operating Activities | -$5.1M | -$7.5M |
| Exercise of warrants | $2.7M | |
| Private placement of warrants | $2.0M | |
| Warrant inducement offer - exercise proceeds | $2.1M | $2.5M |
| Exercise of pre-funded warrants | $210 | |
| Payment of offering costs | -$40.2K | |
| At the market issuance of stock proceeds | $1.4M | |
| Registration and issuance costs associated with warrant issuance | -$366.6K | -$588.0K |
| Net Cash Provided By Financing Activities | $3.7M | $5.9M |
| Net Decrease in Cash | -$1.4M | -$1.6M |
| Warrant modifications - incremental value | $1.8M | $3.0M |
| Accounts payable and accrued expenses for offering costs | $98.9K | $17.1K |
No quarter-by-quarter statement was filed.
Leadership
Who has led ZyVersa Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
2025
- Chief executive officerSteve C. Glover Dec 13, 2022 to now11
- Chief financial officerPeter Wolfe Dec 13, 2022 to now12
- Chief financial officerDavid S. Briones Dec 20, 2021 to Mar 10, 202213
Board members and other officers (13)
- Chief Medical OfficerPablo A. Guzman Jan 26, 2023 to now14
- Chief Commercial OfficerKaren A. Cashmere Dec 13, 2022 to now15
- Chief Scientific OfficerNicholas A. Labella Jr. Dec 13, 2022 to Dec 14, 202216
- Board memberKaren A. Cashmere Jul 18, 2024 to now17
- Board memberGregory Gene Freitag Jan 17, 2023 to now18
- Board memberJames Sapirstein Jan 17, 2023 to now19
- Board memberKatrin Rupalla Jan 17, 2023 to Jan 17, 202320
- Board memberMin-Chul Park Dec 13, 2022 to now21
- Board memberRobert G. Finizio Dec 13, 2022 to now22
- Board memberSteve C. Glover Dec 13, 2022 to now11
- Board memberChristopher Twitty Dec 20, 2021 to Mar 10, 202223
- Board memberDavid S. Briones Dec 20, 2021 to Mar 10, 202213
- Board memberGregory Skalicky Dec 20, 2021 to Mar 10, 202224
Former names
- Larkspur Health Acquisition Corp.May 13, 2021 to Dec 9, 20222
Timeline
- Dec 13, 2022New chief executive Steve C. Glover becomes CEO11
Filings
307 filings to the SEC since October 2021: 6 annual reports, 13 quarterly reports, 52 major events, 51 insider forms, 25 large holders, 160 other. The latest 20:
- Jul 16, 20268-K EDGAR
- Jul 10, 20268-K EDGAR
- May 13, 202610-Q EDGAR
- Mar 31, 202610-K EDGAR
- Mar 5, 20268-K EDGAR
- Dec 3, 20258-K EDGAR
- Nov 19, 20258-K EDGAR
- Nov 19, 202510-Q EDGAR
- Nov 14, 2025NT 10-Q EDGAR
- Oct 15, 20258-K EDGAR
- Oct 6, 202525-NSE EDGAR
- Sep 18, 20258-K EDGAR
- Aug 14, 2025SCHEDULE 13G/A EDGAR
- Aug 13, 202510-Q EDGAR
- Aug 6, 2025EFFECT EDGAR
- Aug 5, 2025CORRESP EDGAR
- Aug 1, 2025CORRESP EDGAR
- Aug 1, 2025S-1/A EDGAR
- Jul 30, 2025UPLOAD EDGAR
- Jul 28, 20258-K EDGAR
The 307 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- ARMISTICE CAPITAL, LLCSCHEDULE 13G/A, 2 filings May 15, 2025 to Aug 14, 202525
- Anson Funds Management LPSC 13G/A, 2 filings Feb 14, 2024 to Nov 14, 202426
- Ionic Ventures, LLCSC 13G/A, 2 filings May 3, 2023 to Feb 14, 202427
- L1 Capital Global Opportunities Master Fund, Ltd.SC 13G/A, 2 filings Jul 18, 2023 to Feb 9, 202428
- INCON Co., Ltd.SC 13G/A, 2 filings Feb 14, 2023 to Jan 19, 202429
- Daniel J. O'ConnorSC 13D/A, 2 filings Dec 22, 2022 to May 12, 202330
- Steve C. GloverSC 13D/A, 2 filings Dec 22, 2022 to May 12, 202331
- A.G.P. / ALLIANCE GLOBAL PARTNERS, LLCSC 13G, 1 filing Feb 14, 202332
- Lighthouse Investment Partners, LLCSC 13G/A, 2 filings Feb 14, 2022 to Feb 14, 202333
- Hudson Bay Capital Management LPSC 13G/A, 2 filings Feb 3, 2022 to Feb 9, 202334
- Yakira Capital Management, Inc.SC 13G/A, 2 filings Feb 9, 2022 to Jan 31, 202335
- Shawn TitcombSC 13G, 1 filing Jan 13, 202336
- Saba Capital Management, L.P.SC 13G, 1 filing Mar 11, 202237
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12SEC EDGARPeter Wolfe, Chief financial officer
- 13
- 14
- 15
- 16
- 17SEC EDGARKaren A. Cashmere, Board member
- 18SEC EDGARGregory Gene Freitag, Board member
- 19SEC EDGARJames Sapirstein, Board member
- 20SEC EDGARKatrin Rupalla, Board member
- 21SEC EDGARMin-Chul Park, Board member
- 22SEC EDGARRobert G. Finizio, Board member
- 23SEC EDGARChristopher Twitty, Board member
- 24SEC EDGARGregory Skalicky, Board member
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37